NBSE · Neubase Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 | Q1 '22 | Q3 '21 | Q2 '21 | Q1 '21 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $5.49M | $1.28M | $1.35M | $4.76M | $6.84M | $4.37M | $2.48M | $3.17M | $2.02M | $1.49M |
| SG&A | $1.20M | $2.40M | $2.60M | $3.60M | $3.09M | $2.94M | $3.47M | $2.72M | $2.64M | $2.33M |
| Total Operating Expenses | $7.72M | $3.69M | $4.60M | $8.36M | $9.93M | $7.30M | $8.84M | $5.90M | $4.66M | $3.82M |
| D&A | $200.0K | $200.0K | $198.6K | $200.0K | $200.0K | $181.5K | $100.0K | $80.0K | $68.1K | $10.0K |
| Operating Income | ($7.72M) | ($3.69M) | ($4.60M) | ($8.36M) | ($9.93M) | ($7.30M) | ($8.84M) | ($5.90M) | ($4.66M) | ($3.82M) |
| Interest Expense | $2.7K | $730 | $1.9K | $2.8K | $3.3K | $15.2K | $3.1K | $6.5K | $9.7K | $1.6K |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($7.63M) | ($3.45M) | ($4.37M) | ($8.49M) | ($9.92M) | ($7.73M) | ($8.66M) | ($5.52M) | ($4.07M) | ($3.80M) |
| EPS - Basic | ($4.73) | ($2.04) | ($0.13) | ($0.26) | ($0.24) | ($0.24) | - | - | - | - |
| EPS - Diluted | ($0.66) | ($2.04) | ($0.13) | ($0.26) | ($0.30) | ($0.24) | - | - | - | - |
Balance Sheet
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 | Q1 '22 | Q3 '21 | Q2 '21 | Q1 '21 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.57M | $14.75M | $13.85M | $23.15M | $38.96M | $47.33M | $52.89M | $24.25M | $27.98M | $31.99M |
| Accounts Receivable | - | - | $150.0K | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $258.6K | $322.1K | $590.2K | $1.84M | $1.62M | $1.19M | $1.81M | $2.18M | $1.18M | $1.51M |
| Current Assets | $13.35M | $15.52M | $14.21M | $24.65M | $40.22M | $48.48M | $54.93M | $24.94M | $28.82M | $32.81M |
| Total Assets | $18.62M | $22.33M | $21.46M | $32.69M | $48.81M | $57.04M | $64.17M | $27.47M | $30.76M | $34.44M |
| Current Liabilities | $4.65M | $6.12M | $1.92M | $4.17M | $4.99M | $4.15M | $4.19M | - | - | - |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $9.48M | $11.09M | $7.01M | $9.50M | $10.64M | $9.91M | $10.10M | $3.54M | $2.24M | $3.15M |
| Stockholders' Equity | $9.14M | $11.25M | $14.45M | $23.19M | $38.16M | $47.13M | $54.07M | $23.94M | $28.52M | $31.29M |
| Retained Earnings | ($116.47M) | ($114.65M) | ($111.21M) | ($102.74M) | ($86.62M) | ($76.70M) | ($68.97M) | ($53.15M) | ($47.63M) | ($43.56M) |
Cash Flow
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 | Q1 '22 | Q3 '21 | Q2 '21 | Q1 '21 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($5.69M) | - | - | ($5.27M) | - | - | ($3.78M) | - |
| Investing Cash Flow | - | - | ($49.8K) | - | - | ($123.9K) | - | - | ($208.5K) | - |
| Financing Cash Flow | - | - | ($28.6K) | - | - | ($175.0K) | - | - | ($26.1K) | - |
| CapEx | - | - | $49.8K | - | - | $123.9K | - | $800.0K | $193.6K | - |
| Free Cash Flow | - | - | ($5.74M) | - | - | ($5.39M) | - | - | ($3.97M) | - |
Ratios
| Metric | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 | Q1 '22 | Q3 '21 | Q2 '21 | Q1 '21 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | 1.31 | - | - | 0.70 | - | - | 0.98 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -41.0% | -15.4% | -20.4% | -26.0% | -20.3% | -13.5% | -13.5% | -20.1% | -13.2% | -11.0% |
| Return on equity | -83.5% | -30.6% | -30.2% | -36.6% | -26.0% | -16.4% | -16.0% | -23.1% | -14.3% | -12.1% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.87 | 2.53 | 7.40 | 5.92 | 8.07 | 11.69 | 13.10 | - | - | - |
| Quick ratio | 2.87 | 2.53 | 7.40 | 5.92 | 8.07 | 11.69 | 13.10 | - | - | - |
| Cash ratio | 2.70 | 2.41 | 7.21 | 5.56 | 7.81 | 11.41 | 12.61 | - | - | - |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -2867.9x | -5052.0x | -2462.7x | -2965.8x | -2994.4x | -480.0x | -2875.4x | -912.7x | -478.7x | -2431.1x |
| Equity multiplier | 2.04 | 1.99 | 1.49 | 1.41 | 1.28 | 1.21 | 1.19 | 1.15 | 1.08 | 1.10 |
| Liabilities / Assets | 0.51 | 0.50 | 0.33 | 0.29 | 0.22 | 0.17 | 0.16 | 0.13 | 0.07 | 0.09 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 7.6% | 62.9% | 37.0% | 5.4% | -68.4% | -56.7% | -131.1% | -35.4% | -23.2% | -236.4% |
| Net income growth (YoY) | 10.1% | 65.3% | 43.5% | 2.0% | -79.7% | -90.1% | -128.0% | -26.1% | 9.7% | -235.4% |
| EPS growth (YoY) | -153.8% | -580.0% | 45.8% | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | -6.4% | - | - | -35.7% | - | - | -62.8% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -60.6% | -70.5% | -69.3% | -57.1% | 59.4% | 65.3% | 72.8% | 500.1% | 305.8% | 212.0% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing NeuBase Therapeutics against the 5 most active filers in the same SIC group.